Redcare Pharmacy stock falls after 4.1 percent drop as investors weigh strong Rx growth

Published on 09/09/2026 at 11:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redcare Pharmacy stock closed at EUR 56.05 on Xetra on September 8, 2026, down 4.11 percent from the prior close amid SDAX underperformance. Recent company figures show prescription revenue up 58 percent, highlighting robust segment growth.

Automatisiertes Apotheken-Lager mit Robotersystem und unbeschrifteten Medikamentenboxen — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, zeigt automatisiertes Apotheken-Lager mit Roboter-Regalsystem und markenfreien Medikamentenschachteln, Illustration mit AI erstellt.

Redcare Pharmacy N.V. stock (ISIN NL0012044747) ended the Xetra session on September 8, 2026 at EUR 56.05, representing a decline of 4.11 percent compared with the previous closing price of EUR 58.45 and putting the SDAX member under pressure ahead of the next trading day.

Recent price move and SDAX context

According to comdirect Xetra data, the closing price of EUR 56.05 for Redcare Pharmacy on September 8, 2026 was fixed at 17:35 local time, while the prior close stood at EUR 58.45, explaining the daily loss of 4.11 percent on the primary Frankfurt trading venue.

As finanzen.net reported in its SDAX market overview on September 8, 2026, Redcare Pharmacy shares counted among the largest decliners in the index that day, while the SDAX as a whole finished slightly higher, underscoring the relative weakness of Redcare Pharmacy stock compared with its small cap peers.

Rx segment shows strong growth

In contrast to the share price setback, recent company information highlighted that Redcare Pharmacy’s prescription segment is expanding rapidly, with Rx revenue up 58 percent in the latest reported period, signaling strong growth in this core business line and supporting the longer term investment case for the online pharmacy model.

For investors, the combination of a 4.11 percent price drop on September 8, 2026 and a reported 58 percent increase in Rx revenue underlines the tension between short term market consolidation and the company’s operational momentum in prescription-based sales.

Stock level and investor view

Redcare Pharmacy stock last closed on its primary Xetra listing at EUR 56.05 on September 8, 2026, compared with EUR 58.45 a day earlier, and this level leaves the shares clearly below recently reached highs in the low 60 euro range, even as the underlying prescription business continues to grow strongly.